Join to View Full Profile
UH Cleveland Medical Center11100 Euclid Ave Department of Medicine-Hematology and OncologyCleveland, OH 44106
Phone+1 216-844-3951
Fax+1 216-844-5234
Dr. Klisovic is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Ohio State University HospitalFellowship, Hematology and Medical Oncology, 2001 - 2004
University of North Carolina HospitalsResidency, Internal Medicine, 1997 - 2000- Ohio State University College of MedicineClass of 1997
Case Western Reserve UniversityBS, Biomedical Engineering, 1989 - 1993
Certifications & Licensure
OH State Medical License 2001 - 2027
GA State Medical License 2017 - 2022
NC State Medical License 1998 - 2001
American Board of Internal Medicine Medical Oncology
EpicPhysician Builder
Awards, Honors, & Recognition
- CMS Meaningful Use Stage Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2012, 2014, 2016-2017
- CMS Meaningful Use Stage Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2012, 2014, 2016-2017
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Clinical Trials
- Combination of GTI-2040 and Cytarabine in the Treatment of Refractory and Relapsed Acute Myeloid Leukemia (AML) Start of enrollment: 2007 Aug 01
- Correlative Biomarker Study in Patients With Myeloproliferative Disorders Start of enrollment: 2007 Apr 01
- Phase I Combination of Midostaurin, Bortezomib, and Chemo in Relapsed/Refractory Acute Myeloid Leukemia Start of enrollment: 2010 Aug 01
Publications & Presentations
PubMed
- Pharmacologic Targeting of miR29b with Bortezomib and Sorafenib to Improve Decitabine Sensitivity in Patients with Acute Myeloid Leukemia: Results from a Phase 1 Dose-...Shivani Handa, Kristin Koenig, Qiuhong Zhao, Alice S Mims, Sumithira Vasu
Cancers. 2025-12-23 - 1 citationsPegylated Interferons: Still a Major Player for the Treatment of Myeloproliferative Neoplasms.Michael Daunov, Rebecca B Klisovic
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting. 2025-06-01 - 3 citationsA multicenter phase 2 clinical trial of low-dose subcutaneous decitabine in myelofibrosis.Chenyu Lin, Anand A Patel, Dezheng Huo, Theodore Karrison, Koen van Besien
Blood Advances. 2024-11-26
Authored Content
- Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 MutationJune 2017
Press Mentions
OncLive® Presents State of the Science Summit™ on Hematologic MalignanciesOctober 31st, 2019
Turning Points: Together in Sickness, Married in HealthAugust 1st, 2016
Bone-Marrow Donor Travels from Israel for Wedding of Transplant RecipientApril 29th, 2016
Grant Support
- Gti-2040: An Anti-Sense Strategy To Reduce Ribonucleotide Reductase In AMLNational Cancer Institute2009–2010
Professional Memberships
- Member
- Member
- ASBMTMember
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
